{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+1+Hypertension&page=5",
    "query": {
      "condition": "Stage 1 Hypertension",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 113,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+1+Hypertension&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+1+Hypertension&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T00:58:54.145Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01520116",
      "title": "Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Stage 1 - ATS907 - Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - ATS907 - Dose 4",
          "type": "DRUG"
        },
        {
          "name": "Stage 1 - Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Stage 2 - ATS907 - Dose A - to be selected based on Stage 1",
          "type": "DRUG"
        },
        {
          "name": "Stage 2 - ATS907 - Dose B - to be selected based on Stage 1",
          "type": "DRUG"
        },
        {
          "name": "Timoptic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altheos, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2012-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 5,
      "location_summary": "Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Saint Joseph",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520116"
    },
    {
      "nct_id": "NCT04402385",
      "title": "Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pre-Eclampsia",
        "Stage 1 Hypertension",
        "Elevated Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Aspirin 81 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2020-08-06",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402385"
    },
    {
      "nct_id": "NCT01180062",
      "title": "Safety Study of Latanoprost Slow Release Insert",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Arm 2",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost SR insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Moore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-08",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180062"
    },
    {
      "nct_id": "NCT00522925",
      "title": "A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "PS433540",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ligand Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 280,
      "start_date": "2007-08",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2011-09-16",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 15,
      "location_summary": "Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00522925"
    },
    {
      "nct_id": "NCT01415505",
      "title": "Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Nebivolol, Valsartan and Hydrochlorothiazide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 812,
      "start_date": "2011-08",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 135,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415505"
    },
    {
      "nct_id": "NCT02266394",
      "title": "Hypoxia and Inflammatory Injury in Human Renovascular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Artery Stenosis",
        "Ischemic Nephropathy",
        "Renovascular Disease",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Mesenchymal stem cell",
          "type": "DRUG"
        },
        {
          "name": "Mesenchymal stem cell delivery with stent placement",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-10-21",
      "completion_date": "2020-09-25",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266394"
    },
    {
      "nct_id": "NCT03683186",
      "title": "A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PAH",
        "Pulmonary Hypertension",
        "Pulmonary Arterial Hypertension",
        "Hypertension",
        "Connective Tissue Diseases",
        "Familial Primary Pulmonary Hypertension",
        "Vascular Diseases",
        "Cardiovascular Diseases",
        "Hypertension, Pulmonary",
        "Lung Diseases",
        "Respiratory Tract Disease"
      ],
      "interventions": [
        {
          "name": "Ralinepag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-09-23",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03683186"
    },
    {
      "nct_id": "NCT05822245",
      "title": "A Study of PER-001 in Participants With Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "PER-001 Intravitreal Implant - Low Dose",
          "type": "DRUG"
        },
        {
          "name": "PER-001 Intravitreal Implant - High Dose",
          "type": "DRUG"
        },
        {
          "name": "PER-001 Intravitreal Implant - Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perfuse Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-05-25",
      "completion_date": "2025-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05822245"
    },
    {
      "nct_id": "NCT03901781",
      "title": "Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "ST266 via Intranasal Delivery",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2019-10-23",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03901781"
    },
    {
      "nct_id": "NCT01873885",
      "title": "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo Single IV (Intravenous) Infusion",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Single IV Infusion Vasomera (PB1046)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-03T00:58:54.145Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873885"
    }
  ]
}